Literature DB >> 710025

The predictable relationship between plasma levels and dose during chronic propranolol therapy.

T Walle, E C Conradi, U K Walle, T C Fagan, T E Gaffney.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 710025     DOI: 10.1002/cpt1978246668

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


× No keyword cloud information.
  32 in total

1.  Pharmacokinetic and pharmacodynamic comparison of two doses of long acting propranolol (80 and 160 mg) in healthy subjects.

Authors:  B Flouvat; I Berlin; A Cournot; D Robinet; J Duchier; H Sarmini; A Rossi
Journal:  Br J Clin Pharmacol       Date:  1989-05       Impact factor: 4.335

2.  Partial metabolic clearances as determinants of the oral bioavailability of propranolol.

Authors:  T Walle; U K Walle; L S Olanoff; E C Conradi
Journal:  Br J Clin Pharmacol       Date:  1986-09       Impact factor: 4.335

3.  Antihypertensive effect and degree of beta-adrenoceptor blockade after short-term and semi-chronic propranolol therapy.

Authors:  F H Leenen; P Boer; E J Dorhout Mees
Journal:  Br J Clin Pharmacol       Date:  1984-06       Impact factor: 4.335

Review 4.  Clinical pharmacokinetics of beta-adrenoceptor blocking drugs in thyroid disease.

Authors:  J Feely
Journal:  Clin Pharmacokinet       Date:  1983 Jan-Feb       Impact factor: 6.447

5.  Dose dependent changes in propranolol half life when used as an adjunct to neuroleptic treatment.

Authors:  D H Staniforth; N J Yorkston; S A Zaki
Journal:  Psychopharmacology (Berl)       Date:  1982       Impact factor: 4.530

6.  Chronic propranolol administration during pregnancy. Maternal pharmacokinetics.

Authors:  M T Smith; I Livingstone; M J Eadie; W D Hooper; E J Triggs
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

7.  Antihypertensive effect of propranolol at rest and during exercise.

Authors:  F H Leenen; P Boer; E J Dorhout Mees
Journal:  Br J Clin Pharmacol       Date:  1983-03       Impact factor: 4.335

8.  Early kinetics of intravenous propranolol.

Authors:  T C Fagan; T Walle; U K Walle; E C Conradi; G Harmon; T E Gaffney
Journal:  Br J Clin Pharmacol       Date:  1982-04       Impact factor: 4.335

Review 9.  Management of the hypertensive patient who smokes.

Authors:  H Pardell; R Tresserras; E Saltó; P Armario; R Hernández
Journal:  Drugs       Date:  1998-08       Impact factor: 9.546

10.  Pharmacokinetics of bendroflumethiazide alone and in combination with propranolol and hydralazine.

Authors:  M Schäfer-Korting; E Mutschler
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.